Hot or Not, Stock Market Edition: 05/14/2026

Happy Thursday. Here are the stock stories we're following today:

• Hot: Pharmaceutical player Viatris (VTRS) is quietly executing an epic turnaround story; the volatility is real for biotech contender Protagonist Therapeutics (PTGX), but so is the upside potential
• Not: Oil & gas midstream operator Kinetik Holdings (KNTK) just delivered a sucker punch to investors; battery tech hopeful QuantumScape (QS) continues to struggle

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

At Any Given Moment, Only 8% of Stocks Are Worth Owning

The other 92%? They'll waste your time, your money, or both. Louis Navellier has spent 47 years building a system that separates the 8% from everything else - and he's offering 3 FREE searches so you can see where your stocks fall. A? B? C? F? Find out in seconds. No credit card required.

See Which Grade Your Stocks Earn

🔥 HOT: Biotech contender Protagonist Therapeutics (PTGX) is rapidly turning from a speculative pipeline story into a serious growth contender. While the stock has only advanced about 2% in the past month, signs point to near-term acceleration. The biggest catalyst is clinical and regulatory execution. Momentum accelerated after the company’s psoriasis treatment gained FDA approval, while excitement continues building around its broader pipeline — especially Rusfertide, which still has major commercial potential ahead. That progress is transforming investor perception from “promising biotech” to “potential revenue-generating platform,” and Wall Street is responding with increasingly bullish targets and upgraded expectations. The market is also rewarding the company for finally showing profitability and accelerating growth, a rare combination in biotech. According to WallStreetZen, PTGX holds a top-tier Zen Rating (A / Strong Buy), powered by an A in Growth and strong support from Sentiment and Financials, placing it among the highest-rated biotech stocks in the market. 

TL;DR? This is exactly the kind of biotech setup momentum investors look for: major regulatory wins, expanding commercial potential, and a pipeline that still offers upside beyond the current story. The volatility will be real — but so is the opportunity.

🥶 NOT: Battery tech hopeful QuantumScape (QS) keeps generating excitement — but the stock still looks far ahead of the business itself. What’s going on? The core issue is that QuantumScape remains a pre-revenue commercialization story, meaning investors are still betting on what the company could become rather than what it is today. Yes, milestones like the Eagle Line pilot facility and initial licensing revenue helped spark a huge short-term rally, but those developments don’t change the bigger challenge: mass-producing solid-state batteries at scale is incredibly difficult, expensive, and years from full adoption. Meanwhile, the company continues burning cash with limited near-term earnings visibility, which makes the stock highly dependent on market optimism staying elevated. According to WallStreetZen, QS carries a near-bottom-tier F (Strong Sell) rating, weighed down by weak Financials, Safety, Value, and overall quality metrics.

The bottom line? Avoid. The technology may eventually matter — but right now, QuantumScape is still a high-risk science project wrapped in a public stock, and that’s a dangerous setup when execution risk is this high.

🔥 HOT: Pharmaceutical player Viatris (VTRS) is quietly pulling off one of the more impressive turnarounds in healthcare — and the market is finally starting to notice, with the stock gaining roughly 10% in the past week alone. The biggest catalyst is a shift from cost-cutting to actual growth. After years of restructuring and integration work following the Mylan-Upjohn merger, Viatris is now showing improving margins, stronger branded drug performance, and renewed international growth, especially in China. That transition showed up clearly in the latest quarter, where the company delivered a major earnings beat and accelerating revenue trends that signaled the turnaround may be becoming sustainable. Analysts have responded with renewed bullishness, and the stock’s momentum reflects growing institutional confidence that this is no longer just a “cheap pharma” story. According to WallStreetZen, VTRS holds an elite Zen Rating (A / Strong Buy), with standout strength in Growth and strong support across Value, Momentum, Sentiment, and Safety. 

The verdict? This looks like a classic re-rating setup — improving fundamentals, expanding profitability, and a market that may still be underestimating how much the business has stabilized.

🥶 NOT: Oil & gas midstream operator Kinetik Holdings’ (KNTK) latest earnings report exposed some real structural concerns. The company delivered a sharp earnings disappointment. It swung to a loss and missed revenue expectations despite touting record EBITDA. Investors looked past the headline metrics and focused on the bigger issue: deteriorating profitability and a balance sheet that’s becoming harder to defend. Kinetik’s negative equity position and weak return metrics are major warning signs in a capital-intensive business that depends on stable financing conditions. Even worse, future earnings are projected to decline while much of the broader midstream industry is still expected to grow — a bad combination in a sector where consistency matters. According to WallStreetZen, KNTK now sits at the very bottom of its industry with an F (Strong Sell) rating, dragged down by weak Growth, Value, and Sentiment scores. 

All said? This is a company with balance sheet stress, weakening earnings power, and limited upside catalysts, which is exactly the type of setup investors should avoid — especially when stronger energy names are available elsewhere.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.